PharmD Info

A forum for Indian Pharmacy Professionals

Important: Registered today to have the complete access on this forum --- Register Here
Its an open online platform to share and discuss clinical research and publication related topics to develop your skills and knowledge on various research methodologies and its related outcome measurements.Eg:Statistical Analysis,Study Designs and Journal Clubs.
Forum rules: Dear User, Kindly read our forum rules before you proceed with our PharmD Info, Your first 5 posts/topics requires moderator approval and this website is purely meant for educational and knowledge sharing purpose only so you should not make any topics/replies/messages which criticize, threaten or abuse any member, pharmacy governing bodies and organizations. Your post will be deleted automatically by our BB Pruning System if your topic is not viewed by members for more than 5 days. So, make sure that your topics and its related contents are unique and valuable. We expect you to be an active member of our forum to continue with your free membership.Kindly note that if a member received more than five warnings from moderator/members they will be blocked automatically by our Bulletin Board system.
  • User avatar
#697
THE NATIONALInstitute ofPharmaceutical Education and Research, Ahmedabad (NIPER-A), on Wednesday claimed to have developed new class of compounds for treatment of Type II diabetes and also perfected the manufacturing process for it. Its director Kiran Kalia, while addressing mediapersons here, said the chemical molecules developed by the insti-tute was different from other drugs available in the mar-ket. The institute, she said, had filed application seeking patent for it.She claimed that the drug was more efficient and cost-effective than the other drugs for diabetes.
The institute,however, was yet to approach the pharma companies for its commercial manufacturing and sale in the market. Stating that her institute is also focussing on developing new drugs against tuberculosis and resistant TB strains,Kalia claimed NIPER-A had developed as many as eight molecules exhibiting potent activity against Rifampicin-resistant strain of tuberculosis.
The institute conducts MS (Pharma) and doctoral courses. So far, 84 students have passed out from the insti-tute and 92 are currently studying for different postgrad-uate courses. A total of 15 students have enrolled for PhD programmes. The institute, which is among seven national institutes set up in 2007 by the Centre, is currently operat-ing from MB Institute of Mental Health in Ahmedabad.
Attachments
1.jpg
Similar Topics
Topics Statistics Last post
0 Replies 
1099 Views
by Admin
18 Sep 2017, 07:03
NIPER Joint Entrance Exam-2018
by Admin  - 25 Mar 2018, 14:27  - In: Pharma Magazine
0 Replies 
504 Views
by Admin
25 Mar 2018, 14:27
0 Replies 
1108 Views
by Admin
02 Feb 2017, 21:49
0 Replies 
785 Views
by Admin
28 Aug 2017, 14:38
0 Replies 
857 Views
by Admin
03 Sep 2017, 15:52

Tags

Hello Everyone

This is the best thing i do today to be a member i[…]

https://i.imgur.com/WzzIkLJ.jpg

https://i.imgur.com/xUyNEY4.jpg

Dear Sir/Madam, This is for your kind information[…]

WELCOME TO OUR E-LEARN COURSE WORK MODULES